ERBB2 and neoplasm: Immunochemistry information was available for 79% of the patients; most tumours were ER and/or PR positive and HER2 negative (44%), followed by ER and/or PR positive and HER2 positive tumour type (17%), triple negative tumours (12%) and ER and PR negative/HER2 positive (7%).